Agenus reports 48% 3-year overall survival in Phase 1b BOT+BAL ovarian cancer study

Agenus reported 48% 3-year overall survival in its Phase 1b BOT+BAL study for recurrent ovarian cancer, unchanged from the 2-year estimate in a heavily pretreated group. Updated follow-up data were presented at IGC2026.

Detected & updated continuously · Source: Nebula